Literature DB >> 25142067

Palliative treatment for symptomatic malignant pericardial effusion†.

Guled M Jama1, Marco Scarci2, Jack Bowden3, Stefan J Marciniak4.   

Abstract

Consensus has yet to emerge regarding the optimal choice of therapy in the management of malignant pericardial effusion. We review the literature to evaluate the existing evidence on the clinical effectiveness of surgical and interventional cardiological approaches. A formal literature search for all studies addressing the treatment of pericardial effusion in cancer patients was undertaken using predefined keywords. Abstracts were screened and reviewed, and data extracted. Data on intervention type, number of patients treated, number of patients surviving the procedure, effusion recurrences, need for further interventions and procedure-related complications were obtained from each study and collated in a quantitative synthesis. Of 1181 articles identified, 59 contained sufficient quantitative information to be included in the synthesis. A total of 2322 patients with symptomatic pericardial effusion were identified, of which 1399 patients were reported to have underlying malignancy. Three surgical approaches were described in a total of 19 studies, with overall success rates ranging from 93.3 to 100% and associated complication rates ranging from 4.5 to 10.3%. The remaining 40 studies reported four non-surgical treatment modalities, with success rates of 55.1-90.4% and complication rates of 5.9-32%. Data from the literature suggest that surgical drainage of the pericardium is superior to non-surgical approaches for symptom relief, effusion recurrence and morbidity; however, the lack of randomized controlled trials means that selection bias remains an important limitation to the field and definitive adequately controlled trials should be a priority.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Malignant pericardial effusion; Sclerosant; Surgery

Mesh:

Year:  2014        PMID: 25142067     DOI: 10.1093/icvts/ivu267

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  18 in total

1.  Extenuating symptoms is very important for malignant pericardial effusion.

Authors:  Wenhui Gong; Qiang Zhao
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

2.  Symptomatic malignant pericardial effusion due to advanced pericardial malignancies: a palliative approach.

Authors:  Nauman Khalid; Lovely Chhabra; Sarah Aftab Ahmad; David H Spodick
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 3.  Landmark Trials in the Surgical Management of Mesothelioma.

Authors:  Taylor Kantor; Elliot Wakeam
Journal:  Ann Surg Oncol       Date:  2021-01-31       Impact factor: 5.344

4.  Pericardiocentesis versus pericardiotomy for malignant pericardial effusion: a retrospective comparison.

Authors:  C Labbé; L Tremblay; Y Lacasse
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

Review 5.  Pericardial Disease Associated with Malignancy.

Authors:  Ryan Schusler; Shari L Meyerson
Journal:  Curr Cardiol Rep       Date:  2018-08-20       Impact factor: 2.931

6.  Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion.

Authors:  Danielle El Haddad; Cezar Iliescu; Syed Wamique Yusuf; William Nassib William; Tarif H Khair; Juhee Song; Elie N Mouhayar
Journal:  J Am Coll Cardiol       Date:  2015-09-08       Impact factor: 24.094

7.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

Review 8.  Case study-based systematic review of literature on lymphoma-associated cardiac tamponade.

Authors:  Mohammad Abrar Shareef; Abdulaziz M Eshaq; Rasha Alshawaf; Emad Alharthi; Arwa A Al Muslat; Reema AbuDawas; Abdulhadi A AlAmodi
Journal:  Contemp Oncol (Pozn)       Date:  2021-02-23

9.  Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion.

Authors:  Gianmauro Numico; Antonella Cristofano; Marcella Occelli; Marco Sicuro; Alessandro Mozzicafreddo; Elena Fea; Ida Colantonio; Marco Merlano; Pierluigi Piovano; Nicola Silvestris
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

10.  Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review.

Authors:  Dawei Chen; Yan Zhang; Fang Shi; Minghuan Li; Hui Zhu; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2015-10-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.